Centre Hospitalier Universitaire de Nice, Service d'Infectiologie and Université de Nice Sophia-Antipolis, Faculté de Médecine, France.
Clin Infect Dis. 2012 Jan 15;54(2):268-74. doi: 10.1093/cid/cir838.
In view of the alarming spread of antimicrobial resistance in the absence of new antibiotics, this study aimed at assessing the availability of potentially useful older antibiotics. A survey was performed in 38 countries among experts including hospital pharmacists, microbiologists, and infectious disease specialists in Europe, the United States, Canada, and Australia. An international expert panel selected systemic antibacterial drugs for their potential to treat infections caused by resistant bacteria or their unique value for specific criteria. Twenty-two of the 33 selected antibiotics were available in fewer than 20 of 38 countries. Economic motives were the major cause for discontinuation of marketing of these antibiotics. Fourteen of 33 antibiotics are potentially active against either resistant Gram-positive or Gram-negative bacteria. Urgent measures are then needed to ensure better availability of these antibiotics on a global scale.
鉴于新抗生素的缺乏导致抗菌药物耐药性的惊人传播,本研究旨在评估潜在有用的旧抗生素的供应情况。在欧洲、美国、加拿大和澳大利亚的 38 个国家中,对包括医院药剂师、微生物学家和传染病专家在内的专家进行了一项调查。一个国际专家小组根据其治疗耐药菌引起的感染的潜力或针对特定标准的独特价值选择了全身性抗菌药物。在 38 个国家中,有 22 种被选中的抗生素在不到 20 个国家/地区有供应。经济动机是这些抗生素停止上市的主要原因。在 33 种抗生素中有 14 种对耐药革兰氏阳性或革兰氏阴性细菌具有潜在活性。因此,需要采取紧急措施确保这些抗生素在全球范围内更广泛的供应。